Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
May 23, 2023
Revance to Participate in Upcoming Investor Conferences
May 9, 2023
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
May 2, 2023
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 5, 2023
Revance to Participate in the Needham 22nd Annual Healthcare Conference
March 30, 2023
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
March 7, 2023
Revance to Participate in Upcoming Investor Conferences
February 28, 2023
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
February 27, 2023
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
February 23, 2023
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
Displaying 1 - 10 of 309